Regeneron And Sanofi Win FDA Approval For Their Expected Mega Blockbuster Eczema Drug Dupixent

The FDA has approved the eczema drug dupilumab (to be branded as Dupixent) from Regeneron Pharmaceuticals and Sanofi which is likely to become a mega-blockbuster franchise worth upwards of $5 billion a year for these two partners.